# A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer

> **NCT07560124** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Akeso** · enrollment: 286 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** AK138D1
- **DRUG:** Ivonescimab
- **DRUG:** treatment of physician's choice

## Key facts

- **NCT ID:** NCT07560124
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-06
- **Primary completion:** 2028-06-06
- **Final completion:** 2030-09-14
- **Target enrollment:** 286 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07560124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07560124, "A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07560124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*